Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leiomyoma | 20 | 2024 | 26 | 13.160 |
Why?
|
Uterine Neoplasms | 15 | 2024 | 36 | 9.670 |
Why?
|
MicroRNAs | 16 | 2021 | 386 | 5.430 |
Why?
|
Myocytes, Smooth Muscle | 6 | 2020 | 84 | 2.530 |
Why?
|
Malnutrition | 7 | 2014 | 45 | 2.120 |
Why?
|
Mediator Complex | 3 | 2024 | 3 | 2.110 |
Why?
|
Prenatal Exposure Delayed Effects | 11 | 2020 | 155 | 2.050 |
Why?
|
Muscle, Smooth, Vascular | 7 | 2017 | 127 | 1.980 |
Why?
|
Epigenesis, Genetic | 6 | 2019 | 198 | 1.960 |
Why?
|
Glucocorticoids | 7 | 2018 | 80 | 1.900 |
Why?
|
Endometrium | 8 | 2012 | 57 | 1.850 |
Why?
|
Myometrium | 7 | 2024 | 12 | 1.790 |
Why?
|
Transforming Growth Factor beta3 | 2 | 2023 | 5 | 1.680 |
Why?
|
Female | 75 | 2024 | 19873 | 1.570 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 781 | 1.560 |
Why?
|
Extracellular Matrix | 3 | 2021 | 111 | 1.240 |
Why?
|
Cell Proliferation | 7 | 2021 | 1149 | 1.180 |
Why?
|
Fetal Nutrition Disorders | 3 | 2015 | 9 | 1.150 |
Why?
|
Dexamethasone | 2 | 2017 | 43 | 1.150 |
Why?
|
RNA, Messenger | 12 | 2022 | 1152 | 1.130 |
Why?
|
Nitric Oxide | 5 | 2008 | 287 | 1.110 |
Why?
|
Neovascularization, Physiologic | 3 | 2013 | 70 | 1.110 |
Why?
|
Extracellular Matrix Proteins | 3 | 2018 | 68 | 1.070 |
Why?
|
Humans | 52 | 2024 | 34853 | 1.020 |
Why?
|
Transcription Factor RelA | 3 | 2020 | 37 | 1.000 |
Why?
|
Nitric Oxide Synthase | 4 | 2008 | 103 | 1.000 |
Why?
|
Tryptophan | 2 | 2022 | 62 | 0.990 |
Why?
|
Cell Cycle Proteins | 2 | 2018 | 220 | 0.990 |
Why?
|
Pregnancy | 23 | 2020 | 1503 | 0.940 |
Why?
|
Aging | 11 | 2011 | 639 | 0.930 |
Why?
|
Ovary | 3 | 2014 | 101 | 0.870 |
Why?
|
Amino Acid Transport Systems, Neutral | 1 | 2022 | 2 | 0.870 |
Why?
|
Interleukin-8 | 4 | 2020 | 59 | 0.830 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 5 | 0.820 |
Why?
|
DNA Methylation | 3 | 2019 | 301 | 0.810 |
Why?
|
Transcription, Genetic | 4 | 2017 | 550 | 0.770 |
Why?
|
Progesterone | 3 | 2015 | 117 | 0.730 |
Why?
|
Cells, Cultured | 9 | 2021 | 1442 | 0.720 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2013 | 157 | 0.710 |
Why?
|
Fetal Growth Retardation | 4 | 2018 | 51 | 0.700 |
Why?
|
Rats | 23 | 2017 | 3261 | 0.700 |
Why?
|
Tumor Cells, Cultured | 5 | 2021 | 480 | 0.700 |
Why?
|
Adult | 22 | 2021 | 11034 | 0.690 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 112 | 0.690 |
Why?
|
Gene Expression Regulation, Enzymologic | 3 | 2021 | 160 | 0.660 |
Why?
|
Rats, Sprague-Dawley | 13 | 2020 | 1534 | 0.660 |
Why?
|
Nitric Oxide Synthase Type III | 5 | 2012 | 63 | 0.660 |
Why?
|
Hypothalamo-Hypophyseal System | 3 | 2014 | 49 | 0.650 |
Why?
|
Mutation | 4 | 2024 | 1023 | 0.640 |
Why?
|
Middle Aged | 16 | 2021 | 9642 | 0.620 |
Why?
|
I-kappa B Kinase | 2 | 2014 | 40 | 0.610 |
Why?
|
Anti-Allergic Agents | 1 | 2016 | 2 | 0.600 |
Why?
|
Animals | 36 | 2023 | 14307 | 0.600 |
Why?
|
Pregnancy Complications | 2 | 2010 | 132 | 0.600 |
Why?
|
Epithelial Cells | 3 | 2008 | 366 | 0.590 |
Why?
|
Gene Expression Profiling | 3 | 2023 | 600 | 0.580 |
Why?
|
Signal Transduction | 5 | 2021 | 1802 | 0.560 |
Why?
|
Corticosterone | 2 | 2015 | 73 | 0.560 |
Why?
|
Endothelium, Vascular | 3 | 2013 | 229 | 0.550 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2012 | 605 | 0.550 |
Why?
|
Prenatal Nutritional Physiological Phenomena | 1 | 2015 | 14 | 0.540 |
Why?
|
Down-Regulation | 5 | 2021 | 420 | 0.540 |
Why?
|
Carotid Arteries | 1 | 2015 | 29 | 0.530 |
Why?
|
Menopause, Premature | 1 | 2014 | 5 | 0.520 |
Why?
|
Leiomyosarcoma | 1 | 2014 | 3 | 0.520 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 8 | 0.510 |
Why?
|
Menstrual Cycle | 5 | 2006 | 34 | 0.510 |
Why?
|
Transcription Factors | 3 | 2024 | 653 | 0.490 |
Why?
|
Hysterectomy | 3 | 2021 | 29 | 0.490 |
Why?
|
Fetal Development | 2 | 2013 | 29 | 0.490 |
Why?
|
Aorta | 3 | 2010 | 161 | 0.490 |
Why?
|
Maternal-Fetal Exchange | 1 | 2013 | 29 | 0.480 |
Why?
|
Cyclin-Dependent Kinase 2 | 3 | 2020 | 30 | 0.470 |
Why?
|
Blood Vessels | 1 | 2013 | 32 | 0.470 |
Why?
|
Genitalia, Female | 2 | 2004 | 26 | 0.470 |
Why?
|
Inflammation Mediators | 1 | 2014 | 120 | 0.460 |
Why?
|
Estrogen Replacement Therapy | 4 | 2002 | 44 | 0.460 |
Why?
|
Collagen Type III | 4 | 2020 | 7 | 0.460 |
Why?
|
Carrier Proteins | 3 | 2023 | 287 | 0.450 |
Why?
|
Infertility, Female | 2 | 2012 | 24 | 0.450 |
Why?
|
Abortion, Habitual | 1 | 2012 | 1 | 0.450 |
Why?
|
Receptors, Aryl Hydrocarbon | 2 | 2004 | 45 | 0.440 |
Why?
|
Gene Expression Regulation | 2 | 2017 | 968 | 0.440 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 756 | 0.440 |
Why?
|
Dehydroepiandrosterone | 3 | 1997 | 8 | 0.440 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2015 | 984 | 0.420 |
Why?
|
Metyrapone | 4 | 2018 | 5 | 0.410 |
Why?
|
Genital Neoplasms, Female | 2 | 2002 | 10 | 0.410 |
Why?
|
Growth Hormone-Releasing Hormone | 2 | 2001 | 2 | 0.410 |
Why?
|
Food Deprivation | 1 | 2011 | 30 | 0.410 |
Why?
|
Melanocyte-Stimulating Hormones | 6 | 1986 | 7 | 0.410 |
Why?
|
Adrenal Glands | 1 | 2011 | 17 | 0.400 |
Why?
|
Uterus | 2 | 2002 | 54 | 0.400 |
Why?
|
Testosterone | 4 | 2014 | 181 | 0.400 |
Why?
|
Steroids | 1 | 2011 | 43 | 0.400 |
Why?
|
Blastocyst | 2 | 2002 | 48 | 0.390 |
Why?
|
Menopause | 2 | 2001 | 54 | 0.380 |
Why?
|
Growth Hormone | 6 | 2001 | 31 | 0.380 |
Why?
|
Gene Expression | 3 | 2018 | 639 | 0.370 |
Why?
|
Transfection | 3 | 2015 | 496 | 0.360 |
Why?
|
Caloric Restriction | 3 | 2014 | 29 | 0.360 |
Why?
|
Animals, Newborn | 7 | 2020 | 323 | 0.360 |
Why?
|
Maternal Nutritional Physiological Phenomena | 3 | 2014 | 23 | 0.360 |
Why?
|
Inflammation | 1 | 2014 | 577 | 0.360 |
Why?
|
Immune System | 2 | 2001 | 40 | 0.350 |
Why?
|
Polycystic Ovary Syndrome | 2 | 2006 | 26 | 0.340 |
Why?
|
Semen | 2 | 2006 | 48 | 0.340 |
Why?
|
Lung | 3 | 2018 | 413 | 0.330 |
Why?
|
Smoke | 1 | 2008 | 39 | 0.330 |
Why?
|
Androgens | 2 | 2014 | 87 | 0.320 |
Why?
|
Sermorelin | 2 | 1997 | 2 | 0.320 |
Why?
|
Pituitary Gland | 8 | 1988 | 59 | 0.310 |
Why?
|
Hypothalamus | 8 | 1989 | 122 | 0.300 |
Why?
|
Spermatozoa | 2 | 2006 | 191 | 0.300 |
Why?
|
Vascular Diseases | 1 | 2007 | 30 | 0.300 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2006 | 27 | 0.290 |
Why?
|
Disease Models, Animal | 4 | 2023 | 1300 | 0.290 |
Why?
|
Clomiphene | 1 | 2006 | 2 | 0.290 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2006 | 18 | 0.290 |
Why?
|
Ovulation Induction | 1 | 2006 | 6 | 0.290 |
Why?
|
Ventricular Remodeling | 1 | 2007 | 59 | 0.290 |
Why?
|
Ovulation | 1 | 2006 | 20 | 0.280 |
Why?
|
Cell Movement | 3 | 2018 | 545 | 0.270 |
Why?
|
Luteinizing Hormone | 7 | 1989 | 62 | 0.270 |
Why?
|
Phosphorylation | 3 | 2015 | 878 | 0.270 |
Why?
|
Elastin | 2 | 2015 | 37 | 0.270 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2015 | 47 | 0.270 |
Why?
|
Nicotinic Agonists | 2 | 2020 | 68 | 0.260 |
Why?
|
Metformin | 1 | 2006 | 64 | 0.260 |
Why?
|
Embryo Implantation | 2 | 2002 | 29 | 0.260 |
Why?
|
Placenta | 2 | 2002 | 91 | 0.260 |
Why?
|
Urinary Tract Physiological Phenomena | 1 | 2004 | 1 | 0.260 |
Why?
|
Adenosine Monophosphate | 1 | 2004 | 7 | 0.260 |
Why?
|
Luciferases | 1 | 2004 | 62 | 0.260 |
Why?
|
Caspase 7 | 2 | 2014 | 16 | 0.260 |
Why?
|
Male | 22 | 2018 | 18870 | 0.250 |
Why?
|
Postmenopause | 3 | 2014 | 125 | 0.250 |
Why?
|
Estradiol | 5 | 2015 | 244 | 0.240 |
Why?
|
Estrogens | 1 | 2005 | 190 | 0.240 |
Why?
|
SOXC Transcription Factors | 1 | 2023 | 2 | 0.240 |
Why?
|
Prolactin | 6 | 1986 | 59 | 0.240 |
Why?
|
Immunity | 3 | 2001 | 51 | 0.240 |
Why?
|
Genes, cdc | 1 | 2023 | 8 | 0.240 |
Why?
|
Caspase 3 | 2 | 2014 | 194 | 0.240 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2023 | 32 | 0.240 |
Why?
|
Binding Sites | 2 | 2015 | 597 | 0.230 |
Why?
|
Nicotine | 2 | 2020 | 238 | 0.230 |
Why?
|
Mice, SCID | 1 | 2023 | 143 | 0.230 |
Why?
|
DNA Mutational Analysis | 1 | 2023 | 89 | 0.230 |
Why?
|
Cell Culture Techniques | 2 | 2017 | 136 | 0.230 |
Why?
|
Pregnancy, Multiple | 1 | 2002 | 6 | 0.220 |
Why?
|
Serotonin | 2 | 2022 | 114 | 0.220 |
Why?
|
Ligases | 1 | 2022 | 6 | 0.220 |
Why?
|
Kynurenic Acid | 1 | 2022 | 9 | 0.220 |
Why?
|
NAD | 1 | 2022 | 39 | 0.210 |
Why?
|
Promoter Regions, Genetic | 2 | 2014 | 484 | 0.210 |
Why?
|
Nitric Oxide Synthase Type II | 3 | 2008 | 91 | 0.210 |
Why?
|
Time Factors | 4 | 2015 | 1681 | 0.210 |
Why?
|
Multigene Family | 1 | 2021 | 105 | 0.200 |
Why?
|
Nuclear Proteins | 1 | 2023 | 287 | 0.200 |
Why?
|
Gonadal Steroid Hormones | 1 | 2001 | 50 | 0.200 |
Why?
|
Body Composition | 5 | 2014 | 146 | 0.200 |
Why?
|
Collagen Type I | 2 | 2020 | 27 | 0.200 |
Why?
|
Fibroblasts | 2 | 2020 | 252 | 0.200 |
Why?
|
Receptors, Progesterone | 1 | 2021 | 78 | 0.200 |
Why?
|
RNA | 1 | 2023 | 234 | 0.200 |
Why?
|
Protein Multimerization | 1 | 2021 | 97 | 0.190 |
Why?
|
Human Growth Hormone | 2 | 1997 | 20 | 0.190 |
Why?
|
Embryo Transfer | 1 | 2000 | 34 | 0.190 |
Why?
|
Immunohistochemistry | 3 | 2012 | 859 | 0.190 |
Why?
|
Fertilization in Vitro | 1 | 2000 | 56 | 0.190 |
Why?
|
Age Factors | 6 | 2020 | 1007 | 0.190 |
Why?
|
Fibrosis | 2 | 2020 | 146 | 0.190 |
Why?
|
Hypertension | 1 | 2007 | 770 | 0.180 |
Why?
|
Sex Characteristics | 3 | 1997 | 213 | 0.180 |
Why?
|
Neuropeptide Y | 3 | 1989 | 23 | 0.180 |
Why?
|
Heart Diseases | 1 | 2020 | 99 | 0.180 |
Why?
|
Cell Line | 2 | 2017 | 1289 | 0.170 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 2128 | 0.170 |
Why?
|
Myocardium | 1 | 2020 | 224 | 0.160 |
Why?
|
DNA-Binding Proteins | 1 | 2002 | 522 | 0.160 |
Why?
|
Cyclin D1 | 1 | 2018 | 42 | 0.160 |
Why?
|
Base Sequence | 2 | 2014 | 932 | 0.160 |
Why?
|
Ascitic Fluid | 2 | 1995 | 7 | 0.160 |
Why?
|
Arterioles | 2 | 2007 | 18 | 0.150 |
Why?
|
Molecular Sequence Data | 2 | 2014 | 1490 | 0.150 |
Why?
|
Follicle Stimulating Hormone | 3 | 1989 | 41 | 0.150 |
Why?
|
Birth Weight | 2 | 2007 | 93 | 0.140 |
Why?
|
Aged | 8 | 2002 | 6448 | 0.140 |
Why?
|
Endometriosis | 2 | 1995 | 69 | 0.140 |
Why?
|
Sheep | 2 | 2012 | 70 | 0.140 |
Why?
|
Sp1 Transcription Factor | 1 | 2015 | 44 | 0.140 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 391 | 0.130 |
Why?
|
Collagen Type IV | 1 | 2015 | 48 | 0.130 |
Why?
|
Premenopause | 2 | 2008 | 103 | 0.130 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 67 | 0.130 |
Why?
|
Cyclins | 1 | 2014 | 35 | 0.130 |
Why?
|
RNA Interference | 1 | 2015 | 225 | 0.130 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 2014 | 22 | 0.130 |
Why?
|
Ovariectomy | 4 | 2014 | 104 | 0.120 |
Why?
|
Lymphokines | 1 | 1993 | 11 | 0.120 |
Why?
|
Gonadotropin-Releasing Hormone | 4 | 1989 | 29 | 0.120 |
Why?
|
Sexuality | 1 | 2014 | 50 | 0.120 |
Why?
|
Animal Nutritional Physiological Phenomena | 1 | 2013 | 9 | 0.120 |
Why?
|
Lymphocele | 1 | 1993 | 1 | 0.120 |
Why?
|
Sclerotherapy | 1 | 1993 | 3 | 0.120 |
Why?
|
Inguinal Canal | 1 | 1993 | 4 | 0.120 |
Why?
|
Cerebrovascular Circulation | 1 | 2014 | 71 | 0.120 |
Why?
|
Cell Differentiation | 2 | 2014 | 562 | 0.120 |
Why?
|
Bleomycin | 1 | 1993 | 18 | 0.120 |
Why?
|
Nutritional Status | 1 | 2014 | 114 | 0.120 |
Why?
|
Radioimmunoassay | 5 | 2006 | 66 | 0.120 |
Why?
|
Infant, Premature | 1 | 2013 | 128 | 0.110 |
Why?
|
Up-Regulation | 1 | 2015 | 490 | 0.110 |
Why?
|
Myosin Heavy Chains | 1 | 2012 | 19 | 0.110 |
Why?
|
Rats, Inbred Strains | 9 | 1986 | 132 | 0.110 |
Why?
|
Insulin-Like Growth Factor I | 3 | 1997 | 66 | 0.110 |
Why?
|
Stromal Cells | 1 | 2012 | 45 | 0.110 |
Why?
|
Mice | 1 | 2023 | 5668 | 0.110 |
Why?
|
Epithelium | 1 | 2012 | 74 | 0.110 |
Why?
|
Blotting, Western | 2 | 2008 | 834 | 0.110 |
Why?
|
Arteries | 1 | 2012 | 67 | 0.110 |
Why?
|
NF-kappa B | 1 | 2014 | 306 | 0.100 |
Why?
|
Contractile Proteins | 1 | 2011 | 8 | 0.100 |
Why?
|
Carotid Artery, Common | 1 | 2011 | 9 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 31 | 0.100 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2013 | 283 | 0.100 |
Why?
|
Cardiovascular Diseases | 2 | 2014 | 628 | 0.100 |
Why?
|
Somatostatin | 4 | 1986 | 22 | 0.100 |
Why?
|
Infant, Newborn | 1 | 2013 | 871 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2013 | 296 | 0.090 |
Why?
|
Cytokines | 1 | 1993 | 569 | 0.090 |
Why?
|
Follicular Phase | 1 | 2008 | 5 | 0.090 |
Why?
|
Reference Values | 3 | 2007 | 204 | 0.090 |
Why?
|
B-Lymphocytes | 2 | 2001 | 181 | 0.080 |
Why?
|
Ascorbic Acid | 1 | 2008 | 63 | 0.080 |
Why?
|
Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 13 | 0.080 |
Why?
|
Obesity | 2 | 2007 | 965 | 0.080 |
Why?
|
Hemoglobins | 1 | 2008 | 101 | 0.080 |
Why?
|
Arginine | 1 | 2008 | 62 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2001 | 392 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2004 | 1056 | 0.080 |
Why?
|
Glutathione | 1 | 2008 | 160 | 0.080 |
Why?
|
Ovarian Neoplasms | 2 | 2002 | 303 | 0.080 |
Why?
|
Stress, Physiological | 2 | 1985 | 137 | 0.080 |
Why?
|
Benzo(a)pyrene | 1 | 2008 | 122 | 0.080 |
Why?
|
Splanchnic Circulation | 1 | 2007 | 4 | 0.080 |
Why?
|
Periodicity | 2 | 1997 | 33 | 0.080 |
Why?
|
Lymphocyte Subsets | 2 | 1997 | 19 | 0.080 |
Why?
|
Mesenteric Arteries | 1 | 2007 | 18 | 0.080 |
Why?
|
Vascular Resistance | 1 | 2007 | 32 | 0.080 |
Why?
|
Apoptosis | 1 | 2014 | 1317 | 0.080 |
Why?
|
Endorphins | 1 | 1986 | 4 | 0.070 |
Why?
|
Pituitary Hormones, Anterior | 1 | 1986 | 2 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2001 | 341 | 0.070 |
Why?
|
Limbic System | 1 | 1987 | 25 | 0.070 |
Why?
|
Hormone Antagonists | 1 | 2006 | 15 | 0.070 |
Why?
|
Gestational Age | 2 | 2020 | 190 | 0.070 |
Why?
|
Glycogen | 1 | 2006 | 17 | 0.070 |
Why?
|
Macaca mulatta | 2 | 2002 | 122 | 0.070 |
Why?
|
Mifepristone | 1 | 2006 | 33 | 0.070 |
Why?
|
Estrus | 2 | 1985 | 14 | 0.070 |
Why?
|
Fertility Agents, Female | 1 | 2006 | 6 | 0.070 |
Why?
|
Hyperinsulinism | 1 | 2006 | 17 | 0.070 |
Why?
|
Sperm Motility | 1 | 2006 | 37 | 0.070 |
Why?
|
Biogenic Amines | 1 | 1986 | 10 | 0.070 |
Why?
|
Drug Combinations | 1 | 2006 | 89 | 0.070 |
Why?
|
Infertility | 1 | 2006 | 17 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 145 | 0.070 |
Why?
|
Cell Count | 1 | 2006 | 129 | 0.070 |
Why?
|
Estrogen Antagonists | 1 | 2005 | 26 | 0.070 |
Why?
|
Antioxidants | 1 | 2008 | 386 | 0.070 |
Why?
|
Fetus | 3 | 2012 | 103 | 0.070 |
Why?
|
Alanine Transaminase | 1 | 2005 | 26 | 0.070 |
Why?
|
Isoenzymes | 1 | 2005 | 149 | 0.070 |
Why?
|
Kinetics | 3 | 1997 | 650 | 0.070 |
Why?
|
Urethra | 1 | 2004 | 2 | 0.070 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2004 | 3 | 0.060 |
Why?
|
Cystitis | 1 | 2004 | 6 | 0.060 |
Why?
|
Urinary Bladder, Neurogenic | 1 | 2004 | 3 | 0.060 |
Why?
|
Urinary Tract | 1 | 2004 | 7 | 0.060 |
Why?
|
Urinary Bladder | 1 | 2004 | 28 | 0.060 |
Why?
|
Hydrocarbons | 1 | 2004 | 2 | 0.060 |
Why?
|
Dioxins | 1 | 2004 | 8 | 0.060 |
Why?
|
ARNTL Transcription Factors | 1 | 2004 | 16 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2006 | 152 | 0.060 |
Why?
|
Neurotransmitter Agents | 1 | 2004 | 57 | 0.060 |
Why?
|
Spectrophotometry | 1 | 2004 | 71 | 0.060 |
Why?
|
Insulin | 1 | 2006 | 224 | 0.060 |
Why?
|
Spinal Cord Injuries | 1 | 2004 | 60 | 0.060 |
Why?
|
Infertility, Male | 1 | 2004 | 44 | 0.060 |
Why?
|
Phenotype | 2 | 2018 | 650 | 0.060 |
Why?
|
Liver | 2 | 2008 | 447 | 0.060 |
Why?
|
DNA Primers | 1 | 2004 | 269 | 0.060 |
Why?
|
Age Determination by Skeleton | 1 | 2003 | 1 | 0.060 |
Why?
|
Ovarian Function Tests | 1 | 2003 | 1 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 79 | 0.060 |
Why?
|
Growth | 1 | 2003 | 12 | 0.060 |
Why?
|
Bone Diseases, Metabolic | 1 | 2003 | 9 | 0.060 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2003 | 11 | 0.060 |
Why?
|
Pregnancy Reduction, Multifetal | 1 | 2002 | 1 | 0.060 |
Why?
|
Amino Acid Sequence | 2 | 2004 | 1124 | 0.060 |
Why?
|
Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2002 | 2 | 0.050 |
Why?
|
Hirsutism | 1 | 2001 | 1 | 0.050 |
Why?
|
Acne Vulgaris | 1 | 2001 | 7 | 0.050 |
Why?
|
Fallopian Tubes | 1 | 2002 | 16 | 0.050 |
Why?
|
Treatment Outcome | 1 | 2006 | 1349 | 0.050 |
Why?
|
Safety | 1 | 2001 | 48 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2002 | 197 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2001 | 15 | 0.050 |
Why?
|
Granulocytes | 1 | 2001 | 28 | 0.050 |
Why?
|
Bone and Bones | 1 | 2001 | 89 | 0.050 |
Why?
|
Protein Binding | 1 | 2004 | 913 | 0.050 |
Why?
|
Lipid Metabolism | 1 | 2001 | 109 | 0.050 |
Why?
|
Diet | 1 | 2007 | 747 | 0.050 |
Why?
|
Pregnancy Rate | 1 | 2000 | 14 | 0.050 |
Why?
|
Sperm Injections, Intracytoplasmic | 1 | 2000 | 67 | 0.050 |
Why?
|
Cohort Studies | 1 | 2004 | 1422 | 0.050 |
Why?
|
Endometrial Neoplasms | 1 | 2001 | 64 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2007 | 881 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2004 | 465 | 0.040 |
Why?
|
Monocytes | 1 | 2001 | 258 | 0.040 |
Why?
|
Rabbits | 3 | 1989 | 278 | 0.040 |
Why?
|
Pituitary Gland, Anterior | 4 | 1985 | 10 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2005 | 1961 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2001 | 239 | 0.040 |
Why?
|
Injections, Intraventricular | 3 | 1989 | 60 | 0.040 |
Why?
|
Cognition | 1 | 2001 | 373 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 1997 | 46 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 1997 | 4 | 0.040 |
Why?
|
Skinfold Thickness | 1 | 1997 | 7 | 0.040 |
Why?
|
Placebos | 1 | 1997 | 38 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 1997 | 22 | 0.040 |
Why?
|
Interleukin-2 | 1 | 1997 | 87 | 0.040 |
Why?
|
Single-Blind Method | 1 | 1997 | 50 | 0.040 |
Why?
|
Hormones | 1 | 1997 | 51 | 0.040 |
Why?
|
Bone Density | 1 | 1996 | 76 | 0.040 |
Why?
|
Receptors, Interleukin-2 | 1 | 1995 | 29 | 0.030 |
Why?
|
Muscles | 1 | 1995 | 64 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 1995 | 102 | 0.030 |
Why?
|
Thyrotropin-Releasing Hormone | 2 | 1986 | 11 | 0.030 |
Why?
|
Administration, Oral | 1 | 1995 | 212 | 0.030 |
Why?
|
Double-Blind Method | 1 | 1995 | 269 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 1995 | 222 | 0.030 |
Why?
|
Substance P | 2 | 1985 | 25 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 1997 | 212 | 0.030 |
Why?
|
Cytoprotection | 1 | 2014 | 32 | 0.030 |
Why?
|
Tissue Extracts | 2 | 1984 | 10 | 0.030 |
Why?
|
Muscle Strength | 1 | 2014 | 26 | 0.030 |
Why?
|
Middle Cerebral Artery | 1 | 2014 | 16 | 0.030 |
Why?
|
Vasoconstriction | 1 | 2014 | 40 | 0.030 |
Why?
|
Pulmonary Surfactant-Associated Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
Arousal | 1 | 2014 | 82 | 0.030 |
Why?
|
Brain | 2 | 1996 | 1268 | 0.030 |
Why?
|
Chemokine CCL5 | 1 | 1993 | 38 | 0.030 |
Why?
|
Drainage | 1 | 1993 | 11 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2013 | 32 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 1993 | 25 | 0.030 |
Why?
|
Phthalazines | 1 | 2012 | 4 | 0.030 |
Why?
|
Phospholipids | 1 | 2013 | 68 | 0.030 |
Why?
|
Interferon-gamma | 1 | 1993 | 235 | 0.030 |
Why?
|
Weight Gain | 1 | 2013 | 128 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2014 | 257 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 117 | 0.030 |
Why?
|
Pyridines | 1 | 2012 | 113 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 396 | 0.030 |
Why?
|
Myosin-Light-Chain Kinase | 1 | 2011 | 5 | 0.030 |
Why?
|
Myosin Light Chains | 1 | 2011 | 5 | 0.030 |
Why?
|
Tunica Media | 1 | 2011 | 14 | 0.030 |
Why?
|
Protein Transport | 1 | 2012 | 286 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 19 | 0.030 |
Why?
|
Culture Media, Serum-Free | 1 | 2011 | 40 | 0.030 |
Why?
|
Immune Sera | 3 | 1985 | 59 | 0.030 |
Why?
|
Oxygen | 1 | 2012 | 193 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2011 | 99 | 0.030 |
Why?
|
Muscle Contraction | 1 | 2011 | 63 | 0.020 |
Why?
|
Calcium | 1 | 2014 | 445 | 0.020 |
Why?
|
Potassium | 1 | 2011 | 110 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2011 | 110 | 0.020 |
Why?
|
Actins | 1 | 2011 | 142 | 0.020 |
Why?
|
Castration | 3 | 1985 | 33 | 0.020 |
Why?
|
Sex Factors | 1 | 2013 | 859 | 0.020 |
Why?
|
Cerebral Ventricles | 1 | 1989 | 23 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2014 | 587 | 0.020 |
Why?
|
Lipase | 1 | 2008 | 16 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 1989 | 68 | 0.020 |
Why?
|
PPAR gamma | 1 | 2008 | 49 | 0.020 |
Why?
|
PPAR alpha | 1 | 2008 | 42 | 0.020 |
Why?
|
Copper | 1 | 1989 | 101 | 0.020 |
Why?
|
Triglycerides | 1 | 2008 | 129 | 0.020 |
Why?
|
Fatty Liver | 1 | 2008 | 56 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2008 | 147 | 0.020 |
Why?
|
Chromatography, Gel | 1 | 1987 | 46 | 0.020 |
Why?
|
Orchiectomy | 1 | 1987 | 33 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 1987 | 61 | 0.020 |
Why?
|
beta-Endorphin | 1 | 1986 | 14 | 0.020 |
Why?
|
Neoplasms | 1 | 1996 | 1033 | 0.020 |
Why?
|
Antibodies | 1 | 1987 | 135 | 0.020 |
Why?
|
gamma-Globulins | 1 | 1985 | 5 | 0.020 |
Why?
|
Restraint, Physical | 1 | 1985 | 17 | 0.020 |
Why?
|
Norepinephrine | 1 | 1986 | 107 | 0.020 |
Why?
|
Hypothalamus, Middle | 1 | 1985 | 3 | 0.020 |
Why?
|
Preoptic Area | 1 | 1985 | 15 | 0.020 |
Why?
|
Median Eminence | 1 | 1985 | 10 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1985 | 23 | 0.020 |
Why?
|
Arginine Vasopressin | 1 | 1985 | 13 | 0.020 |
Why?
|
Apomorphine | 1 | 1984 | 13 | 0.020 |
Why?
|
Suprachiasmatic Nucleus | 1 | 1985 | 42 | 0.020 |
Why?
|
Spiperone | 1 | 1984 | 1 | 0.020 |
Why?
|
Dopamine | 1 | 1986 | 232 | 0.020 |
Why?
|
Lipids | 1 | 2005 | 222 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 1983 | 152 | 0.010 |
Why?
|
Body Mass Index | 1 | 2005 | 775 | 0.010 |
Why?
|
Prevalence | 1 | 2005 | 1425 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2005 | 2561 | 0.010 |
Why?
|
Risk Factors | 1 | 2005 | 3414 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 1995 | 55 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 445 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 1989 | 58 | 0.010 |
Why?
|
Pituitary Gland, Posterior | 1 | 1984 | 7 | 0.000 |
Why?
|
Cattle | 1 | 1984 | 472 | 0.000 |
Why?
|